Surgical Management of Non-small Cell Lung Cancer with Synchronous Brain Metastases
Overview
Affiliations
Objectives: Published series on the synchronous combined resection of brain metastases and primary non-small cell lung cancer are small and scarce. We therefore undertook a multicenter retrospective study to determine long-term survival and identify potential prognostic factors.
Design: Our series includes 103 patients who were operated on between 1985 and 1998 for the following tumors: adenocarcinomas (74); squamous cell carcinomas (20); and large cell carcinomas (9). Three patients had two brain metastases, and one patient had three metastases; the remaining patients had a single metastasis. Ninety-three patients presented with neurologic signs that regressed completely after resection in 60 patients and partially, in 26 patients. Neurosurgical resection was incomplete in six patients. Seventy-five patients received postoperative brain radiotherapy. The time interval between the brain operation and the lung resection was < 4 months. Pulmonary resection was incomplete in eight patients.
Results: The survival calculated from the date of the first operation was 56% at 1 year, 28% at 2 years, and 11% at 5 years. Univariate analysis showed a better prognosis for adenocarcinomas (p = 0.019) and a trend toward a better prognosis for patients with small pulmonary tumors (T1 vs T3, p = 0.068), N0 stage disease (N0 vs N+, p = 0.069), and complete pulmonary resection (p = 0.057). In a multivariate analysis, adenocarcinoma histology also affected the survival rate (p = 0.03).
Conclusions: It seems legitimate to proceed with lung resection after complete resection of a single brain metastasis, at least in patients with an adenocarcinoma and a small lung tumor and without abnormal mediastinal lymph nodes seen on the CT scan or during mediastinoscopy.
Multimodal treatment of oligometastatic non-small cell lung cancer.
Graca L, Pego A, Lareiro S, Pancas R BMJ Case Rep. 2023; 16(12).
PMID: 38061851 PMC: 10711880. DOI: 10.1136/bcr-2023-256097.
Vedire Y, Shin S, Groman A, Hennon M, Dy G, Yendamuri S JTO Clin Res Rep. 2023; 4(6):100522.
PMID: 37275564 PMC: 10238748. DOI: 10.1016/j.jtocrr.2023.100522.
Armocida D, Pesce A, Palmieri M, Cofano F, Palmieri G, Cassoni P J Clin Med. 2023; 12(10).
PMID: 37240478 PMC: 10219312. DOI: 10.3390/jcm12103372.
Yang F, Gao L, Wang Q, Gao W Transl Cancer Res. 2023; 12(3):473-489.
PMID: 37033346 PMC: 10080322. DOI: 10.21037/tcr-22-2323.
Wang Q, Li J, Liang X, Zhan Q Front Oncol. 2022; 12:888999.
PMID: 35936705 PMC: 9354689. DOI: 10.3389/fonc.2022.888999.